» Articles » PMID: 8608941

A Reversible, P53-dependent G0/G1 Cell Cycle Arrest Induced by Ribonucleotide Depletion in the Absence of Detectable DNA Damage

Overview
Journal Genes Dev
Specialty Molecular Biology
Date 1996 Apr 15
PMID 8608941
Citations 148
Authors
Affiliations
Soon will be listed here.
Abstract

Cells with a functional p53 pathway undergo a G0/G1 arrest or apoptosis when treated with gamma radiation or many chemotherapeutic drugs. It has been proposed that DNA damage is the exclusive signal that triggers the arrest response. However, we found that certain ribonucleotide biosynthesis inhibitors caused a p53-dependent G0 or early G1 arrest in the absence of replicative DNA synthesis or detectable DNA damage in normal human fibroblasts. CTP, GTP, or UTP depletion alone was sufficient to induce arrest. In contrast to the p53-dependent response to DNA damage, characterized by long-term arrest and irregular cellular morphologies, the antimetabolite-induced arrest was highly reversible and cellular morphologies remained relatively normal. Both arrest responses correlated with prolonged induction of p53 and the Cdk inhibitor P21(WAF1/CIP1/SDI1) and with dephosphorylation of pRb. Thus, we propose that p53 can serve as a metabolite sensor activated by depletion of ribonucleotides or products or processes dependent on ribonucleotides. Accordingly, p53 may play a role in inducing a quiescence-like arrest state in response to nutrient challenge and a senescence-like arrest state in response to DNA damage. These results have important implications for the mechanisms by which p53 prevents the emergence of genetic variants and for developing more effective approaches to chemotherapy based on genotype.

Citing Articles

Deciphering the pseudouridine nucleobase modification in human diseases: From molecular mechanisms to clinical perspectives.

Jia S, Yu X, Deng N, Zheng C, Ju M, Wang F Clin Transl Med. 2025; 15(1):e70190.

PMID: 39834094 PMC: 11746961. DOI: 10.1002/ctm2.70190.


Identification and characterization of a novel upstream promoter of zebrafish p53 gene.

Tian X, Zhu Z, Li W, Zhang J, Han B Mol Biol Rep. 2024; 52(1):15.

PMID: 39589571 DOI: 10.1007/s11033-024-10112-8.


Polydopamine Nanoparticle-Based Combined Chemotherapy and Photothermal Therapy for the Treatment of Liver Cancer.

Emanet M, Lefevre M, Ceccarelli M, Battaglini M, Carmignani A, Schiavone F ACS Appl Mater Interfaces. 2024; 16(31):40695-40713.

PMID: 39058979 PMC: 11310915. DOI: 10.1021/acsami.4c08491.


Mutant p53 reactivation restricts the protumorigenic consequences of wild type p53 loss of heterozygosity in Li-Fraumeni syndrome patient-derived fibroblasts.

Agarwal H, Tal P, Goldfinger N, Chattopadhyay E, Malkin D, Rotter V Cell Death Differ. 2024; 31(7):855-867.

PMID: 38745079 PMC: 11239894. DOI: 10.1038/s41418-024-01307-4.


A fast-acting lipid checkpoint in G1 prevents mitotic defects.

Koberlin M, Fan Y, Liu C, Chung M, Pinto A, Jackson P Nat Commun. 2024; 15(1):2441.

PMID: 38499565 PMC: 10948896. DOI: 10.1038/s41467-024-46696-9.